GENELUX Corp (GNLX) Stock Price, Financials & Summary

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$2.52

From 52W high−69.30%

Volume114268.00

Market cap$114.47M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataSep 18, 2026

Open

$2.52

From 52W high

−69.30%

Volume

114268.00

Market cap

$114.47M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−2.9x

P/E (TTM)

—

RSI (14)

46.1

MomentumView details →

1D Return

+0.00%

YTD Return

−42.10%

SummaryUpdated Jun 1, 2026

Genelux Corporation (NASDAQ:GNLX) is a clinical-stage biopharmaceutical company founded in 2001 and headquartered in Westlake Village, California. The company went public in January 2023 and specializes in developing innovative oncolytic viral immunotherapies designed to treat aggressive and difficult-to-treat solid tumors. Genelux represents a new frontier in cancer treatment, utilizing genetically modified viruses that can selectively target and destroy cancer cells while potentially stimulating the patient's immune system to fight the disease.

Ask drillr about GENELUX Corp →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−2.9x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

7.1x

ProfitabilityView details →

Gross Margin

−1762.50%

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−209.73%

ROA (TTM)

−128.96%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

−2.30%

FCF YoY

−25.74%

Revenue CAGR 3Y

−91.03%

EPS CAGR 3Y

+9.47%

EBITDA YoY

−15.28%

MomentumView details →

1D Return

+0.00%

YTD Return

−42.10%

1Y Return

−39.32%

RSI (14)

46.1

vs 50D SMA

−7.34%

vs 200D SMA

−14.12%

Capital & dividendView details →

Debt/Equity

0.15x

Current Ratio

2.39x

Quick Ratio

2.39x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.21

EPS Surprise

−6.78%

Beats (12Q)

2/12

Next Q EPS Est

−$0.20

Avg Surprise (4Q)

−4.57%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

8000.00

Net Income (TTM)

−33.79M

Op. CF (TTM)

−25.28M

Next earningsNov 4, 2026 →

Latest newsMore news →

Genelux Corporation reported its second quarter financial results and provided business updates on August 13, 2026.38d ago

Similar companies

Coya Therapeutics, Inc.COYA Milestone Pharmaceuticals Inc.MIST Tiziana Life Sciences LtdTLSA PMV Pharmaceuticals, Inc.PMVP Black Diamond Therapeutics, Inc.BDTX Aardvark Therapeutics, Inc. Common StockAARD Find similar companies →

Latest newsMore news →

Genelux Corporation reported its second quarter financial results and provided business updates on August 13, 2026.38d ago